Frazier Life Sciences Management, L.P.
Q2 2022 13F-HR Holdings
Net value change ($000)
-113,739
(-9.7%)
New positions
2
Sold out positions
3
Turnover %
13.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| HilleVax, Inc. | 101,493 | NEW |
| CHINOOK THERAPEUTICS, INC. | 18,508 | 41.7% |
| ARQT | 17,290 | 10.6% |
| KRYS | 14,284 | 24.8% |
| Gracell Biotechnologies Inc. | 9,085 | 113.2% |
| SNDX | 5,944 | 10.7% |
| Cerevel Therapeutics Holdings, Inc. | 3,393 | 173.6% |
| TRVI | 3,292 | NEW |
| Tricida, Inc. | 3,040 | 17.8% |
| TARS | 2,261 | 9.5% |
Top Reduces (Value $000, Stocks/ETFs)
| IVERIC bio, Inc. | -39,120 | -96.0% |
| PHAT | -30,128 | -38.0% |
| Sierra Oncology, Inc. | -27,191 | -36.2% |
| BCYC | -26,483 | -100.0% |
| VRDN | -20,822 | -64.7% |
| Imago BioSciences, Inc. | -17,471 | -30.5% |
| PCVX | -16,882 | -30.3% |
| PARDES BIOSCIENCES, INC. | -12,429 | -82.7% |
| ALPINE IMMUNE SCIENCES, INC. | -12,137 | -32.3% |
| MIRM | -9,131 | -11.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|